NCT02206087View on ClinicalTrials.gov

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Healthy
Interventions
DRUG

PER977

Reversal of heparin-induced anticoagulation

DRUG

Placebo

Reversal of heparin-induced anticoagulation

DRUG

Heparin Sodium

Trial Locations (1)

66211

Quintiles, Overland Park

All Listed Sponsors
lead

Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.

INDUSTRY

NCT02206087 - Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin | Biotech Hunter | Biotech Hunter